THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...
Repatha works by blocking a specific enzyme in your liver to help your body remove cholesterol more effectively. It is not an immunosuppressant drug, so it doesn’t work by suppressing the immune ...
Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...
The US Food and Drug Administration (FDA) has approved Amgen's cholesterol-lowering medication, Repatha (evolocumab) injection, a human monoclonal antibody that inhibits proprotein convertase ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback